Skip to main content
Top
Published in: Clinical Rheumatology 1/2014

01-01-2014 | Brief Report

Two-year clinical and radiologic follow-up of early RA patients treated with initial step up monotherapy or initial step down therapy with glucocorticoids, followed by a tight control approach: lessons from a cohort study in daily practice

Authors: D. De Cock, G. Vanderschueren, S. Meyfroidt, J. Joly, R. Westhovens, P. Verschueren

Published in: Clinical Rheumatology | Issue 1/2014

Login to get access

Abstract

The objective of the study was to evaluate the effect of initial disease-modifying antirheumatic drug (DMARD) combination therapy with steroids (ICTS) and DMARD monotherapy (IMT) on the clinical and radiologic evolution of patients with early rheumatoid arthritis (RA) over a 2-year treatment period, applying tight control (TC) in daily practice. Seventy-four DMARD-naive early RA patients received ICTS or IMT in a TC setting. Baseline and year 1 and year 2 X-rays of hands and feet were scored according to Sharp/van der Heijde. Rapid radiographic progression (RRP) was defined as total Sharp score (TSS) of >5 units/year. At year 1, both treatment groups achieved 50 % remission. At year 2, 37 % of IMT and 60 % of ICTS patients were in remission, despite ICTS patients having initially a more severe RA profile. RRP was found in 4/74 patients at year 1: 3 IMT and 1 ICTS patients. Remarkably, three of these four patients had no radiographic progression in the second year. Five other patients had RRP in the second year: four IMT and one ICTS patients. In a TC setting, ICTS and IMT can prevent radiographic progression in the majority of patients in the daily practice of a Belgian academic hospital over 2 years. ICTS seems to be more effective than IMT in achieving higher remission rates and less radiographic progression.
Literature
1.
go back to reference Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC et al (1997) Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350(9074):309–318PubMedCrossRef Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC et al (1997) Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350(9074):309–318PubMedCrossRef
2.
go back to reference Calguneri M, Pay S, Caliskaner Z, Apras S, Kiraz S, Ertenli I et al (1999) Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis. Clin Exp Rheumatol 17(6):699–704PubMed Calguneri M, Pay S, Caliskaner Z, Apras S, Kiraz S, Ertenli I et al (1999) Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis. Clin Exp Rheumatol 17(6):699–704PubMed
3.
go back to reference Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M et al (1999) Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 353(9164):1568–1573PubMedCrossRef Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M et al (1999) Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 353(9164):1568–1573PubMedCrossRef
4.
go back to reference Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM et al (2007) Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 146(6):406–415PubMedCrossRef Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM et al (2007) Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 146(6):406–415PubMedCrossRef
5.
go back to reference Verschueren P, Esselens G, Westhovens R (2008) Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis. Rheumatology (Oxford) 47(1):59–64CrossRef Verschueren P, Esselens G, Westhovens R (2008) Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis. Rheumatology (Oxford) 47(1):59–64CrossRef
6.
go back to reference Durnez A, Vanderschueren G, Lateur L, Westhovens R, Verschueren P (2011) Effectiveness of initial treatment allocation based on expert opinion for prevention of rapid radiographic progression in daily practice of an early RA cohort. Ann Rheum Dis 70(4):634–637PubMedCrossRef Durnez A, Vanderschueren G, Lateur L, Westhovens R, Verschueren P (2011) Effectiveness of initial treatment allocation based on expert opinion for prevention of rapid radiographic progression in daily practice of an early RA cohort. Ann Rheum Dis 70(4):634–637PubMedCrossRef
7.
go back to reference Verschueren P, Esselens G, Westhovens R (2009) Predictors of remission, normalized physical function, and changes in the working situation during follow-up of patients with early rheumatoid arthritis: an observational study. Scand J Rheumatol 38(3):166–172PubMedCrossRef Verschueren P, Esselens G, Westhovens R (2009) Predictors of remission, normalized physical function, and changes in the working situation during follow-up of patients with early rheumatoid arthritis: an observational study. Scand J Rheumatol 38(3):166–172PubMedCrossRef
8.
go back to reference Boers M, Verhoeven AC, van der Linden S (1997) Combination therapy in early rheumatoid arthritis: the COBRA study. Ned Tijdschr Geneeskd 141(50):2428–2432PubMed Boers M, Verhoeven AC, van der Linden S (1997) Combination therapy in early rheumatoid arthritis: the COBRA study. Ned Tijdschr Geneeskd 141(50):2428–2432PubMed
9.
go back to reference van der Heijde D (1999) How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 26(3):743–745PubMed van der Heijde D (1999) How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 26(3):743–745PubMed
10.
go back to reference Benhamou M, Rincheval N, Roy C, Foltz V, Rozenberg S, Sibilia J et al (2009) The gap between practice and guidelines in the choice of first-line disease modifying antirheumatic drug in early rheumatoid arthritis: results from the ESPOIR cohort. J Rheumatol 36(5):934–942PubMedCentralPubMedCrossRef Benhamou M, Rincheval N, Roy C, Foltz V, Rozenberg S, Sibilia J et al (2009) The gap between practice and guidelines in the choice of first-line disease modifying antirheumatic drug in early rheumatoid arthritis: results from the ESPOIR cohort. J Rheumatol 36(5):934–942PubMedCentralPubMedCrossRef
11.
go back to reference Schipper LG, Vermeer M, Kuper HH, Hoekstra MO, Haagsma CJ, Den Broeder AA et al (2012) A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. Ann Rheum Dis 71(6):845–850PubMedCrossRef Schipper LG, Vermeer M, Kuper HH, Hoekstra MO, Haagsma CJ, Den Broeder AA et al (2012) A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. Ann Rheum Dis 71(6):845–850PubMedCrossRef
12.
go back to reference Kirwan JR, Bijlsma JW, Boers M, Shea BJ (2007) Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 1, CD006356PubMed Kirwan JR, Bijlsma JW, Boers M, Shea BJ (2007) Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 1, CD006356PubMed
13.
go back to reference Welsing PM, Borm GF, van Riel P (2006) Minimal clinically important difference in radiological progression of joint damage. A definition based on patient perspective. J Rheumatol 33(3):501–507PubMed Welsing PM, Borm GF, van Riel P (2006) Minimal clinically important difference in radiological progression of joint damage. A definition based on patient perspective. J Rheumatol 33(3):501–507PubMed
14.
go back to reference Bruynesteyn K, van der Heijde D, Boers M, Lassere M, Boonen A, Edmonds J et al (2001) Minimal clinically important difference in radiological progression of joint damage over 1 year in rheumatoid arthritis: preliminary results of a validation study with clinical experts. J Rheumatol 28(4):904–910PubMed Bruynesteyn K, van der Heijde D, Boers M, Lassere M, Boonen A, Edmonds J et al (2001) Minimal clinically important difference in radiological progression of joint damage over 1 year in rheumatoid arthritis: preliminary results of a validation study with clinical experts. J Rheumatol 28(4):904–910PubMed
15.
go back to reference Avouac J, Gossec L, Dougados M (2006) Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 65(7):845–851PubMedCrossRef Avouac J, Gossec L, Dougados M (2006) Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 65(7):845–851PubMedCrossRef
Metadata
Title
Two-year clinical and radiologic follow-up of early RA patients treated with initial step up monotherapy or initial step down therapy with glucocorticoids, followed by a tight control approach: lessons from a cohort study in daily practice
Authors
D. De Cock
G. Vanderschueren
S. Meyfroidt
J. Joly
R. Westhovens
P. Verschueren
Publication date
01-01-2014
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 1/2014
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-013-2398-9

Other articles of this Issue 1/2014

Clinical Rheumatology 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.